Results 71 to 80 of about 4,268 (199)

Safety, Tolerability, and Metabolic Effects of Long-Acting Cabotegravir and Rilpivirine in HIV Care: A Comprehensive Review

Viruses
The use of long-acting cabotegravir and rilpivirine (LA CAB/RPV) is a novel approach to manage human immunodeficiency virus (HIV). This injectable regimen offers benefits such as an improved quality of life, reduced stigma and enhanced treatment ...
Martina Bottanelli, Antonella Castagna, Camilla Muccini   +2 more
doaj   +1 more source

Latin America and the Caribbean: Challenges and Opportunities for HIV Treatment and Prevention

Journal of the International AIDS Society, Volume 29, Issue S3, July 2026.
ABSTRACT Introduction In Latin America, there are rising numbers of new HIV acquisitions, while the Caribbean has achieved decreases in both new acquisitions and AIDS‐related deaths. The Latin American and Caribbean (LAC) region has worked towards widely available treatment for people with HIV (PWHIV) within public health systems and, in Latin America,
Mateo Prochazka, Kelika A. Konda, Omar Sued, Hortencia Peralta, Andrea Boccardi, Thiago S. Torres, Monica Alonso, Valdilea Veloso, Beatriz Grinsztejn   +8 more
wiley   +1 more source

A year-long extended release nanoformulated cabotegravir prodrug

Nature Materials, 2020
Long-acting cabotegravir (CAB) extends antiretroviral drug administration from daily to monthly. However, dosing volumes, injection site reactions and health-care oversight are obstacles towards a broad usage. The creation of poloxamer-coated hydrophobic and lipophilic CAB prodrugs with controlled hydrolysis and tissue penetrance can overcome these ...
Tanmay A. Kulkarni, Aditya N. Bade, Brady Sillman, Bhagya Laxmi Dyavar Shetty, Melinda S. Wojtkiewicz, Nagsen Gautam, James R. Hilaire, Sruthi Sravanam, Adam Szlachetka, Benjamin G. Lamberty, Brenda M. Morsey, Howard S. Fox, Yazen Alnouti, JoEllyn M. McMillan, R. Lee Mosley, Jane Meza, Paul L. Domanico, Tai-Yuen Yue, Gary Moore, Benson J. Edagwa, Howard E. Gendelman   +20 more
openaire   +3 more sources

Physiologically-based pharmacokinetic modelling of long-acting injectable cabotegravir and rilpivirine in pregnancy

Aims: Long-acting cabotegravir and rilpivirine have been approved to manage HIV in adults, but data regarding safe use in pregnancy are limited. Physiologically-based pharmacokinetic (PBPK) modelling was used to simulate the approved dosing regimens in ...
Atoyebi, Shakir, Olagunju, Adeniyi, Montanha, Maiara, Waitt, Catriona, Grañana-Castillo, Sandra, Cottura, Nicolas, Bunglawala, Fazila, Siccardi, Marco   +7 more
core   +1 more source

A New Multigram Synthetic Process to Cabotegravir

Cabotegravir, a long-acting integrase strand transfer inhibitor, is clinically used for HIV treatment and prevention. Current synthetic processes for cabotegravir are limited to either low scalability or prolonged reaction times.
Chao Yan, Rui Zhang, Yan Zhao, Lin-xiang Zhao, Bo Jin, Boyang Wu, Jiachen Wen, Xiaoyi Li   +7 more
core   +1 more source

Dynamic choice HIV prevention with long-acting injectable cabotegravir pre-exposure prophylaxis in east, central, southern, and west Africa:a cost-effectiveness modelling analysis [PDF]

BACKGROUND: In randomised controlled trials in Kenya and Uganda, a dynamic choice HIV prevention (DCP) intervention that offered structured choice of biomedical prevention product and opportunity to change products over time substantially improved ...
Havlir, Diane V, Balzer, Laura B, Phillips, Andrew N, Revill, Paul, Sutter, Nicole, Petersen, Maya, Kakande, Elijah, Ayieko, James, Bansi-Matharu, Loveleen, Shade, Starley B, Smith, Jennifer, Hickey, Matthew D, Kabami, Jane, Kamya, Moses R, Chamie, Gabriel   +14 more
core   +1 more source

Awareness and intention to use event‐driven and long‐acting injectable pre‐exposure prophylaxis among adolescent and young men who have sex with men and transgender women in Brazil: a cross‐sectional study

Journal of the International AIDS Society
Introduction New pre‐exposure prophylaxis (PrEP) options, including event‐driven and long‐acting injectable, may enhance HIV prevention strategies among adolescents and youth.
Laio Magno, Beo Oliveira Leite, Alexandre Grangeiro, Lorenza Dezanet, Fabiane Soares, Inês Dourado   +5 more
doaj   +1 more source

Intravenous and Subcutaneous Pharmacokinetic Modeling to Support the Development of Long-Acting Multipurpose Prevention Technology for HIV and Pregnancy

Biomedicines
Background/Objectives: Women and girls, particularly in sub-Saharan Africa, face high risks for both HIV and unintended pregnancy. Inconsistent condom use underscores the need for new multipurpose prevention technologies (MPTs) that combine HIV pre ...
Nathan Engel, Daniel Oliveira, Craig Sykes, Amanda P. Schauer, Jasmine L. King, Thy Le, Soumya Rahima Benhabbour, Mackenzie Cottrell   +7 more
doaj   +1 more source

Healthcare workers’ perspectives on HIV pre-exposure prophylaxis delivery in Sub-Saharan Africa: implications for injectable formulation rollout—a narrative review

Frontiers in Public Health
BackgroundLong-acting injectable Human Immunodeficiency Virus (HIV) pre-exposure prophylaxis (PrEP), particularly cabotegravir, presents a promising HIV prevention option in Sub-Saharan Africa (SSA), where HIV prevalence remains high.
Nomvuselelo Nomzamo Mbatha, Nomakhosi Mpofana, Dumile Gumede   +2 more
doaj   +1 more source

Learning from the first: a qualitative study of the psychosocial benefits and treatment burdens of long‐acting cabotegravir/rilpivirine among early adopters in three U.S. clinics

Journal of the International AIDS Society
Introduction Perspectives on long‐acting injectable cabotegravir/rilpivirine (CAB/RPV‐LA) from HIV health disparity populations are under‐represented in current literature yet crucial to optimize delivery.
Katerina A. Christopoulos, Mollie B. Smith, Priyasha Pareek, Alicia Dawdani, Xavier A. Erguera, Kaylin V. Dance, Ryan S. Walker, Janet Grochowski, Francis Mayorga‐Munoz, Matthew D. Hickey, Mallory O. Johnson, John Sauceda, Jose I. Gutierrez Jr., Elizabeth T. Montgomery, Jonathan A. Colasanti, Lauren F. Collins, Moira C. McNulty, Kimberly A. Koester   +17 more
doaj   +1 more source